Podcasts about koshland science museum

In the final episode of this 3 part video series on how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens, Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, goes in depth on the use of antimicrobial drugs in agriculture, their efficacy, and adverse human health consequences. Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine, discusses policy, regulatory and funding issues around antibiotic resistance. Both Dr. Tollefson and Dr. Levy take a handful of questions from the audience.The series, "Antibiotics: Is a Strong Offense the Best Defense?" was filmed on September 18, 2008 at the Koshland Science Museum in Washington, D.C. Parts 1 and 2 can be found at www.microbeworld.org.

In the final episode of this 3 part video series on how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens, Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, goes in depth on the use of antimicrobial drugs in agriculture, their efficacy, and adverse human health consequences. Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine, discusses policy, regulatory and funding issues around antibiotic resistance. Both Dr. Tollefson and Dr. Levy take a handful of questions from the audience.The series, "Antibiotics: Is a Strong Offense the Best Defense?" was filmed on September 18, 2008 at the Koshland Science Museum in Washington, D.C. Parts 1 and 2 can be found at www.microbeworld.org.

In the final episode of this 3 part video series on how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens, Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, goes in depth on the use of antimicrobial drugs in agriculture, their efficacy, and adverse human health consequences. Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine, discusses policy, regulatory and funding issues around antibiotic resistance. Both Dr. Tollefson and Dr. Levy take a handful of questions from the audience. The series, "Antibiotics: Is a Strong Offense the Best Defense?" was filmed on September 18, 2008 at the Koshland Science Museum in Washington, D.C.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focussed on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focused on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention. Part 3 will be published next week.

On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focussed on manufacturing drugs for chronic illnesses. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

Will we become defenseless against bacteria? Will bacteria always find a way to infect and even kill us? The emergence of antibiotic resistant strains of bacteria poses an enormous problem around the world. Scientists believe that the overuse of antibiotics is increasing the appearance of these pathogens. In the US, increasing casualties resulting from drug resistant staphylococcus infections received wide media attention. While antibiotics only work on bacterial infections, many patients and doctors regard antibiotics as a front-line form of treating any type of infection. Antibiotics are often prescribed because the specific pathogen that is causing an illness is often difficult to determine. In some cases they are used as a preventative measure. But is this the best defense? Are there ways to beat bacteria at their own game? On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 1 of this 3 part video series, Dr. Levy discusses the basics of microbial pathogens, bacteria, and antibiotic resistance. And, Dr. Tollefson outlines the various types and classes of antibiotic drugs, approved uses, and current levels of effectiveness. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

Will we become defenseless against bacteria? Will bacteria always find a way to infect and even kill us? The emergence of antibiotic resistant strains of bacteria poses an enormous problem around the world. Scientists believe that the overuse of antibiotics is increasing the appearance of these pathogens. In the US, increasing casualties resulting from drug resistant staphylococcus infections received wide media attention. While antibiotics only work on bacterial infections, many patients and doctors regard antibiotics as a front-line form of treating any type of infection. Antibiotics are often prescribed because the specific pathogen that is causing an illness is often difficult to determine. In some cases they are used as a preventative measure. But is this the best defense? Are there ways to beat bacteria at their own game? On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens. In part 1 of this 3 part video series, Dr. Levy discusses the basics of microbial pathogens, bacteria, and antibiotic resistance. And, Dr. Tollefson outlines the various types and classes of antibiotic drugs, approved uses, and current levels of effectiveness. Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic resistance. Stuart Levy is also Staff Physician at the Tufts Medical Center and he also serves as the president of The International Alliance for the Prudent Use of Antibiotics. Dr. Tollefson is Assistant Commissioner for Science at the U.S. Food and Drug Administration (FDA). She previously served as Deputy Director of the Center for Veterinary Medicine (CVM), where she led CVM's efforts to implement a risk-based approach to address antimicrobial resistance, fulfilling a 2001 Congressional mandate, and was instrumental in the founding of the National Antimicrobial Resistance Monitoring System for Enteric Bacteria. Tollefson also served as Chief of Epidemiology in the Center for Food Safety and Applied Nutrition where she successfully investigated numerous outbreaks of food borne disease and served as liaison to the Centers for Disease Control and Prevention.

From your local bus route to international air travel, infectious diseases can spread across the globe in a matter of hours. In this video podcast episode filmed at the Koshland Science Museum in Washington, D.C., Stephen Eubank from the Virginia Bioinformatics Institute of Virginia Tech and Daniel Lucey from Georgetown University discuss the role of transportation in the spread of disease and examine the effectiveness of various measures to curb transmission. Stephen Eubank, Ph.D., is a project director at the Network Dynamics and Simulation Science Laboratory at the Virginia Bioinformatics Institute of Virginia Tech. His research focuses on modeling and simulating the spread of disease and regional transportation, and the analysis of complex systems. Daniel Lucey, M.D., M.P.H., is an adjunct professor in the Department of Microbiology and Immunology at Georgetown University, where he is co-director of the master of science program in biohazardous threat agents and emerging infectious diseases. In recent years, his teaching focus has been on SARS, avian flu, and the threat of pandemic human influenza. Resources Learn more about infectious diseases at http://www.koshland-science-museum.org/exhib_infectious/index.jsp Transportation Research Board of the National Academies http://www.trb.org/default.asp Pandemic Flu and Travel http://www.pandemicflu.gov/travel/index.html